Merck EBITDA 2010-2024 | MRK

Merck EBITDA for the quarter ending December 31, 2024 was $5.546B, a 841.44% decline year-over-year.

  • Merck 2024 EBITDA was 24.72B, a 262.14% increase from 2023.
  • Merck 2023 EBITDA was 6.826B, a 69.24% decline from 2022.
  • Merck 2022 EBITDA was 22.191B, a 35.2% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Merck EBITDA 2010-2024 | MRK

  • Merck 2024 EBITDA was 24.72B, a 262.14% increase from 2023.
  • Merck 2023 EBITDA was 6.826B, a 69.24% decline from 2022.
  • Merck 2022 EBITDA was 22.191B, a 35.2% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$823.1B
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
AbbVie (ABBV)$348.4B
Roche Holding AG (RHHBY)$259.5B
Novartis AG (NVS)$218.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B